Exenatide-Linked Phase 3 Islet Transplant Trial Marked Completed

A clinical trial involving exenatide was updated on November 4, 2026. The study, titled "Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol," is registered as NCT00679042. According to the update, the trial has reached a status of completed. The study is listed as a Phase 3 trial. Exenatide is an approved compound and this trial evaluated its use within the UIC islet transplantation protocol for individuals with type 1 diabetes. The completed status indicates that the trial has concluded its planned activities, as recorded on ClinicalTrials.gov. No results or outcome data are included in this update. The record does not specify findings, efficacy, or safety conclusions beyond the status change itself. Readers interested in the specifics of enrollment, methodology, or any posted results should consult the official ClinicalTrials.gov listing directly. This brief reflects only the status update provided and does not characterize the trial's outcomes. For more background on exenatide, including its approved uses and general profile, readers can consult the compound overview for additional context.